Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma Academic Article uri icon


MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Central Nervous System Neoplasms
  • Lymphoma


  • We initiated a prospective multicenter phase II trial using rituximab and temozolomide in immunocompetent patients with progressive or recurrent primary central nervous system lymphoma (PCNSL) based on activity observed in retrospective studies. Treatment consisted of an induction phase with rituximab (750 mg/m(2)) on days 1, 8, 15 and 22 and temozolomide (150 mg/m(2)) days 1-7 and 15-21, followed by six cycles of consolidation temozolomide (150-200 mg/m(2) × 5/28 days), followed by maintenance with methylprednisolone (1 g IV every 28 days) until progression. Sixteen patients were enrolled, and a complete response was seen in 2/14 (14%) evaluable patients. The median progression-free survival was 7 weeks and median overall survival was not reached (median follow-up: 37 months). Treatment was well tolerated, but due to slow accrual and preliminary analysis suggesting futility, the trial was closed early. Given the overall modest activity, this regimen should be reserved for patients who are not candidates for other, more aggressive salvage treatments.

publication date

  • January 2013



  • Academic Article



  • eng

PubMed Central ID

  • PMC4802006

Digital Object Identifier (DOI)

  • 10.3109/10428194.2012.698736

PubMed ID

  • 22656234

Additional Document Info

start page

  • 58

end page

  • 61


  • 54


  • 1